Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 16/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.57 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6867040 | 0.91 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL20389329 | 0.90 | GABRG2 (0.67) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL6869006 | 0.89 | GABRG2 (0.63) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL16840114 | 0.87 | GABRG2 (0.75) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL6868907 | 0.87 | GABRG2 (0.66) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL6870854 | 0.85 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL6872449 | 0.84 | GABRG2 (0.53) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL10626425 | 0.80 | GABRG2 (0.87) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL6873122 | 0.80 | GABRG2 (0.65) | GABRG2GABRB3GABRA5GABRA2GABRB2 | |
| SCHEMBL7037721 | 0.80 | GABRG2 (0.60) | GABRG2GABRB3GABRA5GABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| EP-3555100-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3083569-B1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210253588-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2021-01-14 | — | — | US | disclosed |
| US-10815242-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-13 | — | — | US | disclosed |
| US-20190284196-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2019-09-19 | — | — | US | disclosed |
| US-10329301-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190055258-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2019-02-21 | — | — | US | disclosed |
| WO-2018130868-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2018-06-21 | — | — | US | disclosed |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2015095783-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-1337535-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2004-06-09 | — | — | EP | disclosed |
| US-6743789-B2 | SUBSTITUTED IMIDAZO (1,5-A) (1,2,4) TRIAZOLO (4,3-D) (1,4) BENZODIAZEPINE DERIVATIVES ARE USEFUL FOR TREATING ALZHEIMER'S DISEASE; REACTING A BEZODIAZEPINE DERIVATIVE WITH A HYDRAZIDE DERIVATIVE TO FORM END PRODUCT | HOFFMANN-LA ROCHE INC. | 2004-06-01 | — | — | US | disclosed |
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | GABRG2 15/4885GABRB3 11/4885GABRA5 1/4885 |
| US-10815242-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-20190055258-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 24/4885GABRB3 15/4885GABRA5 2/4885 |
| US-20190284196-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GRM1 | GABRG2 25/4885GABRB3 17/4885GABRA5 2/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-10329301-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-20180170941-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 20/4885GABRB3 15/4885GABRA5 2/4885 |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 22/4885GABRB3 16/4885GABRA5 2/4885 |
| US-11142529-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GRM1 | GABRG2 25/4885GABRB3 17/4885GABRA5 2/4885 |
| US-20210253588-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 19/4885GABRB3 13/4885GABRA5 2/4885 |
| US-20200048268-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | GABRG2 14/4885GABRB3 11/4885GABRA5 1/4885 |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | GABRG2 20/4885GABRB3 15/4885GABRA5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.